Disease due to Mycobacterium kansasii in the Czech Republic: 1984-89. 1995

J Kaustová, and M Chmelík, and D Ettlová, and V Hudec, and H Lazarová, and S Richtrová
National Reference Laboratory for M. kansasii of the Czech Republic, Regional Institute of Hygiene, Ostrava, Czech Republic.

METHODS Endemic area of North Moravia, Czech Republic. OBJECTIVE Evaluate the incidence of human disease due to Mycobacterium kansasii. The follow-up of some bacteriological and clinical features. METHODS A retrospective analysis of M. kansasii patients. RESULTS M. kansasii was isolated from the sputum, tissue and other specimens obtained from 650 persons during the period 1984-89. In only 471 of them was this mycobacterium deemed to be the causative agent, predominantly of lung disease. The most typical radiographic finding in these patients was lung infiltration and/or thin-walled cavity. CONCLUSIONS As in previous years the highest incidence of disease remains in an endemic area of North Moravia. The effects of treatment in follow-up patients were influenced not only by the antituberculosis regimen but also by a high frequency of associated diseases. Sputum conversion within 30 days was not affected by the presence or absence of a cavity. Authors consider water to be the source of infection.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009165 Mycobacterium Infections, Nontuberculous Infections with nontuberculous mycobacteria (atypical mycobacteria): M. kansasii, M. marinum, M. scrofulaceum, M. flavescens, M. gordonae, M. obuense, M. gilvum, M. duvali, M. szulgai, M. intracellulare (see MYCOBACTERIUM AVIUM COMPLEX;), M. xenopi (littorale), M. ulcerans, M. buruli, M. terrae, M. fortuitum (minetti, giae), M. chelonae, M. leprae. Mycobacterium Infections, Atypical,Atypical Mycobacterial Infection, Disseminated,Atypical Mycobacterial Infection, Familial Disseminated,Atypical Mycobacteriosis, Familial,Atypical Mycobacteriosis, Familial Disseminated,Atypical Mycobacterium Infections,Infections, Atypical Mycobacterium,Mycobacterium abscessus Infection,Atypical Mycobacterium Infection,Familial Atypical Mycobacterioses,Familial Atypical Mycobacteriosis,Infection, Mycobacterium abscessus,Infections, Mycobacterium abscessus,Mycobacterioses, Familial Atypical,Mycobacteriosis, Familial Atypical,Mycobacterium Infection, Atypical,Mycobacterium Infection, Nontuberculous,Mycobacterium abscessus Infections,Nontuberculous Mycobacterium Infection,Nontuberculous Mycobacterium Infections
D009170 Nontuberculous Mycobacteria So-called atypical species of the genus MYCOBACTERIUM that do not cause tuberculosis. They are also called tuberculoid bacilli, i.e.: M. abscessus, M. buruli, M. chelonae, M. duvalii, M. flavescens, M. fortuitum, M. gilvum, M. gordonae, M. intracellulare (see MYCOBACTERIUM AVIUM COMPLEX;), M. kansasii, M. marinum, M. obuense, M. scrofulaceum, M. szulgai, M. terrae, M. ulcerans, M. xenopi. Atypical Mycobacteria,Mycobacteria, Atypical,Mycobacterium duvalii,Mycobacterium flavescens,Mycobacterium gilvum,Mycobacterium gordonae,Mycobacterium obuense,Mycobacterium szulgai,Mycobacterium terrae,Mycolicibacter terrae,Mycolicibacterium duvalii,Mycolicibacterium flavescens,Mycolicibacterium gilvum,Mycolicibacterium obuense,Tuberculoid Bacillus,Atypical Mycobacterium,Mycobacterium, Atypical,Non-Tuberculous Mycobacteria,Nontuberculous Mycobacterium
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular

Related Publications

J Kaustová, and M Chmelík, and D Ettlová, and V Hudec, and H Lazarová, and S Richtrová
September 2002, Clinics in chest medicine,
J Kaustová, and M Chmelík, and D Ettlová, and V Hudec, and H Lazarová, and S Richtrová
February 1977, Australian and New Zealand journal of medicine,
J Kaustová, and M Chmelík, and D Ettlová, and V Hudec, and H Lazarová, and S Richtrová
May 2009, The Journal of laryngology and otology,
J Kaustová, and M Chmelík, and D Ettlová, and V Hudec, and H Lazarová, and S Richtrová
November 1977, Kekkaku : [Tuberculosis],
J Kaustová, and M Chmelík, and D Ettlová, and V Hudec, and H Lazarová, and S Richtrová
May 1992, Ceskoslovenska gynekologie,
J Kaustová, and M Chmelík, and D Ettlová, and V Hudec, and H Lazarová, and S Richtrová
June 1971, The Annals of thoracic surgery,
J Kaustová, and M Chmelík, and D Ettlová, and V Hudec, and H Lazarová, and S Richtrová
October 1978, Clinical orthopaedics and related research,
J Kaustová, and M Chmelík, and D Ettlová, and V Hudec, and H Lazarová, and S Richtrová
December 1965, JAMA,
J Kaustová, and M Chmelík, and D Ettlová, and V Hudec, and H Lazarová, and S Richtrová
May 1973, The American review of respiratory disease,
J Kaustová, and M Chmelík, and D Ettlová, and V Hudec, and H Lazarová, and S Richtrová
June 1971, Mayo Clinic proceedings,
Copied contents to your clipboard!